Lupin recalls 43,860 ophthalmic solution bottles in US over impurities


Drug maker Lupin is recalling 43,860 bottles of Moxifloxacin Ophthalmic solution, used to treat bacterial conjunctivitis, in the US market.

The Mumbai-based drug firm is recalling 43,860 bottles (3ml) due to failed impurities or degradation specifications, United States Food and Drug Administration (USFDA) said in an Enforcement Report.

The product is being recalled by Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of the company. The product has been manufactured at Lupin's Pithampur-based manufacturing facility.

USFDA said, the product was distributed by five wholesalers, six drug chains, four mail order pharmacies and one mail order pharmacy or supermarket who may have further distributed it throughout the US.

The US health regulator has classified it as a class-III recall which is initiated in a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Lupin shares were trading at Rs 767.50 apiece, up 0.89 per cent from their previous close, on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel